Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential

Multimodal Sequential Approach in Colorectal Cancer Liver Metastases: Hepatic Resection after Yttrium-90 Selective Internal Radiation Therapy and Cetuximab Rescue Treatment

(2018) Sara Pini et al.   TUMORI

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

(2017) Alfredo Carrato et al.   EUROPEAN JOURNAL OF CANCER

FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer

(2017) Gianluca Tomasello et al.   JAMA Oncology

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

(2017) Alan P. Venook et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion

(2016) Junichi Shindoh et al.   ANNALS OF SURGICAL ONCOLOGY

Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy

(2016) Nancy E. Kemeny et al.   JOURNAL OF SURGICAL ONCOLOGY

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV

(2015) F. A. Lévi et al.   ANNALS OF ONCOLOGY

Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for Patients With Unresectable Hepatic Metastases From Colorectal Cancer

(2015) Michael I. DʼAngelica et al.   ANNALS OF SURGERY

Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

(2015) Eiji Oki et al.   ANNALS OF SURGICAL ONCOLOGY

Long-Term Outcomes of Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastases

(2015) Yoshiaki Maeda et al.   ANNALS OF SURGICAL ONCOLOGY

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)

(2015) Joost Huiskens et al.   BMC CANCER

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hepatic Artery Infusion Chemotherapy for Liver Malignancy

(2015) Julie N. Leal et al.   Surgical Oncology Clinics of North America

Pattern of distant metastases in colorectal cancer: a SEER based study

(2015) Miaozhen Qiu et al.   Oncotarget

Metastatic pattern in colorectal cancer is strongly influenced by histological subtype

(2014) N. Hugen et al.   ANNALS OF ONCOLOGY

Chemotherapy and Targeted Therapy for Patients with Initially Unresectable Colorectal Liver Metastases, Focusing on Conversion Hepatectomy and Long-Term Survival

(2014) Toru Beppu et al.   ANNALS OF SURGICAL ONCOLOGY

KRASmutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases

(2014) Nancy E. Kemeny et al.   CANCER

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases

(2014) Serge Evrard et al.   PLoS One

Treatment of Extensive Metastatic Colorectal Cancer to the Liver with Systemic and Hepatic Arterial Infusion Chemotherapy and Two-Stage Hepatic Resection: The Role of Salvage Therapy for Recurrent Disease

(2013) Kenneth Cardona et al.   ANNALS OF SURGICAL ONCOLOGY

Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases

(2013) GENNARO GALIZIA et al.   ONCOLOGY REPORTS

Does “Conversion Chemotherapy” Really Improve Survival in Metastatic Colorectal Cancer Patients with Liver-Limited Disease?

(2013) K. Kataoka et al.   WORLD JOURNAL OF SURGERY

Unresectable Colorectal Liver Metastases: The Safety and Efficacy of Conversion Therapy Using Hepatic Arterial Infusion Immunochemotherapy with 5-Fluorouracil and Polyethylene Glycol-Interferon α-2a

(2013) Takuya Nakai et al.   WORLD JOURNAL OF SURGERY

Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases

(2013) Nicolas Devaud et al.   HPB

Chance of Cure Following Liver Resection for Initially Unresectable Colorectal Metastases: Analysis of Actual 5-Year Survival

(2012) Francesco Ardito et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

Two-stage hepatectomy for multiple bilobar colorectal liver metastases

(2011) M. Narita et al.   BRITISH JOURNAL OF SURGERY

A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer

(2011) Barbara-Ann Adelstein et al.   EUROPEAN JOURNAL OF CANCER

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictors of cure after hepatic resection of colorectal liver metastases: An analysis of actual 5- and 10-year survivors

(2011) Terence C. Chua et al.   JOURNAL OF SURGICAL ONCOLOGY

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Prolonged Survival of Initially Unresectable Hepatic Colorectal Cancer Patients Treated With Hepatic Arterial Infusion of Oxaliplatin Followed by Radical Surgery of Metastases

(2010) Diane Goéré et al.   ANNALS OF SURGERY

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases

(2010) M Cosimelli et al.   BRITISH JOURNAL OF CANCER

Global Patterns of Cancer Incidence and Mortality Rates and Trends

(2010) A. Jemal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer

(2010) Nancy E. Kemeny et al.   JOURNAL OF CLINICAL ONCOLOGY

Regional Hepatic Chemotherapies in the Treatment of Colorectal Cancer Metastases to the Liver

(2010) Thinn P. Pwint et al.   SEMINARS IN ONCOLOGY

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

(2009) Gianluca Masi et al.   ANNALS OF SURGERY

KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases

(2009) Garrett M. Nash et al.   ANNALS OF SURGICAL ONCOLOGY

Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?

(2009) René Adam et al.   JOURNAL OF CLINICAL ONCOLOGY

Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma

(2009) Nancy E. Kemeny et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current management of colorectal hepatic metastasis

(2009) Skye C Mayo et al.   Expert Review of Gastroenterology & Hepatology

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

(2008) M. Borner et al.   ANNALS OF ONCOLOGY

Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases

(2008) Dennis A. Wicherts et al.   ANNALS OF SURGERY

Survival Outcomes of Patients with Colorectal Liver Metastases Following Hepatic Resection or Ablation in the Era of Effective Chemotherapy

(2008) Mehrdad Nikfarjam et al.   ANNALS OF SURGICAL ONCOLOGY

Inducing Resectability of Chemotherapy Refractory Colorectal Liver Metastasis by Radioembolization With Yttrium-90 Microspheres

(2008) Marc Van den Eynde et al.   CLINICAL NUCLEAR MEDICINE

Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables

(2008) James R. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY